Galactosylceramidase Proteins (GALC)

GALC encodes a lysosomal protein which hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Additionally we are shipping Galactosylceramidase Antibodies (75) and Galactosylceramidase Kits (8) and many more products for this protein.

list all proteins Gene Name GeneID UniProt
GALC 2581 P54803
GALC 14420 P54818
GALC 314360  
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top Galactosylceramidase Proteins at

Showing 6 out of 10 products:

Catalog No. Origin Source Conjugate Images Quantity Delivery Price Details
Escherichia coli (E. coli) Mouse His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 30 to 35 Days
Escherichia coli (E. coli) Human His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 30 to 35 Days
Escherichia coli (E. coli) Rat His tag 100 μg 15 to 18 Days
Escherichia coli (E. coli) Human Un-conjugated SDS-PAGE analysis of Human Galactosylceramidase Protein. 100 μg 11 to 18 Days
Wheat germ Human GST tag 10 μg 11 to 12 Days
Escherichia coli (E. coli) Human His tag   50 μg 9 to 11 Days

GALC Proteins by Origin and Source

Origin Expressed in Conjugate
Human ,
Mouse (Murine)

Rat (Rattus)

More Proteins for Galactosylceramidase (GALC) Interaction Partners

Human Galactosylceramidase (GALC) interaction partners

  1. The present study describes two GALC mutations shared by two Chinese siblings with juvenile-onset of Krabbe disease

  2. rs17203398 associated with mucous membrane pemphigoid

  3. The authors present the structure of a glycosphingolipid-processing complex, revealing how SapA and GALC form a heterotetramer with an open channel connecting the enzyme active site to the SapA hydrophobic cavity.

  4. EMT phenotypes and GALC expression of CTCs are correlated with cancer metastasis and therapeutic outcomes, suggesting them to be potential markers for the prognosis of NSCLC.

  5. Results show for the first time that during normal aging, psychosine metabolism is progressively dysfunctional, leading to its accumulation in the aging brain, especially in regions vulnerable to degeneration in Parkinson's disease (PD). These results underline the possibility that defects in the metabolism mediated by changes in GALC activity modify the risk of developing alpha-synuclein pathology in vulnerable patients.

  6. we showed for the first time the specific alteration of beta-Galctosidase (Gal), beta-Galactosylcerebrosidase (GALC) in MCI patients. It is notable that in above peripheral biological samples the lysosomes are more sensitive to AD cellular metabolic alteration when compared to levels of Abeta-peptide or Tau proteins, similar in both AD groups analyzed

  7. Enzyme activities (acid alpha-glucosidase (GAA), galactocerebrosidase (GALC), glucocerebrosidase (GBA), alpha-galactosidase A (GLA), alpha-iduronidase (IDUA) and sphingomyeline phosphodiesterase-1 (SMPD-1)) were measured on ~43,000 de-identified dried blood spot (DBS) punches, and screen positive samples were submitted for DNA sequencing to obtain genotype confirmation of disease risk

  8. This review illustrated The Krabbe's disease is caused by mutation in the enzyme Beta-galactocerebrosidase.

  9. This is the largest expression study of GALC variants/mutations found in Newborn screening and confirmed KD cases.

  10. We demonstrated that a heterozygous GALC deletion does not play a significant role in the pathogenesis of normal tension glaucoma in a representative clinic-based population of South Koreans, unlike whites.

  11. Mutations in GALC cause late-onset Krabbe disease with predominant cerebellar ataxia

  12. promoter hypermethylation contributed to down-regulation of GALC Gene, implicating epigenetic inactivation of GALC may play a role in tumorigenesis of cancer.

  13. Case Report: compound GALC heterozygosity in a boy with infantile Krabbe disease with severe clinical course.

  14. GALC was downregulated by promoter hypermethylation and contributed to the pathogenesis of EBV-associated nasopharyngeal carcinoma

  15. Genetic variants near IREB2 and GALC likely contribute to genetic susceptibility to PAE associated with COPD.

  16. Itis an exoglycosidase that catalyzes the hydrolysis of terminal beta-linked galactose residues and its deficiencies or mutation cause llysosomal diseases. (review)

  17. Structural snapshots illustrate the catalytic cycle of beta-galactocerebrosidase, the defective enzyme in Krabbe disease.

  18. Higher galactocerebrosidase activity is predictive of later symptom onset times but does not predict survival after symptom onset when controlling for the logarithm of age at onset.

  19. study identified 4 novel mutations of the GALC gene in 2 unrelated Chinese families with Krabbe disease: one insertion mutation, c.1836_1837insT, one nonsense mutation, c.599C>A (p.S200X),one deletion mutation, c.1911 1_1911 5delGTAAG and one missense mutation, c.2041G>A

  20. GALC mutation is associated with Krabbe disease.

Mouse (Murine) Galactosylceramidase (GALC) interaction partners

  1. Data show that transgenic galactocerebrosidase (GALC) activity was mainly localized at the Purkinje cells layer in the cerebellum of the AAV-treated twitcher mice.

  2. The results of this study indicated that the greater neurochemical pathology observed in the optic nerve than in the sciatic nerve of beta-gal -/- mice is likely due to the greater glycolipid storage in optic nerve.

  3. This study demonistrated that galactosylceramidase Deficiency also casue neuromuscular dysfunction.

  4. results show that GALCtwi-5J, a spontaneous mutation in murine GALC precisely matches the E130K missense mutation in patients with infantile Krabbe disease

  5. Insights into the mechanisms underlying galactosylceramidase regulation of early post-natal neurogenic niches improve our understanding of the multi-component pathology of globoid cell leukodystrophy .

  6. The crystal structures of GALC and the GALC-product complex, revealing a novel domain architecture with a previously uncharacterized lectin domain not observed in other hydrolases, are presented.

  7. Data show that GALC and, possibly, other enzymes for the maintenance of niche functionality and health tightly control the concentration of these sphingolipids within HSPCs.

  8. GALC is not restricted to myelinating cells but also to several neuronal cell types in the nervous system, such as hippocampal pyramidal neurons and cerebellar neurons.

  9. Direct administration of these viral particles into the brains of neonatal mice with globoid cell leukodystrophy resulted in sustained expression of GALC activity, improved myelination

  10. mutant oligodendrocytes can internalize exogenous galactocerebrosidase and maintain stable myelin, demonstrating that exogenous enzyme replacement will be a key strategy in the therapy of globoid cell leukodystrophy

  11. Lentiviral vectors were designed and optimized for transfer of Galc expression in Twitcher brain.

  12. Mouse model of globoid cell leukodystrophy contains a premature stop codon (W339X) in the galactosylceramidase (GALC) gene that abolishes enzymatic activity.

  13. These results suggest that GALC deficiency not only affects myelinating glia but also leads to neuronal dysfunction. The contemporaneous neuropathology might help to explain the limited efficacy of current gene and cell therapies.

Galactosylceramidase (GALC) Protein Profile

Protein Summary

This gene encodes a lysosomal protein which hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Mutations in this gene have been associated with Krabbe disease, also known as globoid cell leukodystrophy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Gene names and symbols associated with Galactosylceramidase Proteins (GALC)

  • galactosylceramidase (GALC)
  • galactosylceramidase a (galca)
  • galactosylceramidase (galc)
  • Galactosylceramidase (Caci_7107)
  • Galactosylceramidase (Bacsa_1415)
  • Galactosylceramidase (Spico_0384)
  • Galactosylceramidase (LOC100304802)
  • galactosylceramidase L homeolog (galc.L)
  • galactosylceramidase (Galc)
  • 2310068B06Rik protein
  • A930008M05Rik protein
  • AW212969 protein
  • AW413532 protein
  • Gacy protein
  • galc protein
  • GALCERase protein
  • galcl protein
  • si:ch211-199l3.4 protein
  • twi protein
  • twitcher protein
  • zgc:92561 protein

Protein level used designations for Galactosylceramidase Proteins (GALC)

galactocerebrosidase , GALCERase , galactosylceramidase like , Galactosylceramidase , Galactocerebrosidase , galactocerebroside beta-galactosidase , galactosylceramide beta-galactosidase , galactosylceraminidase , galactosylceramidase (Krabbe disease)

100034130 Equus caballus
449649 Danio rerio
779723 Xenopus (Silurana) tropicalis
8338474 Catenulispora acidiphila DSM 44928
10259317 Bacteroides salanitronis DSM 18170
10494670 Sphaerochaeta coccoides DSM 17374
100304802 Ictalurus punctatus
100195231 Salmo salar
446948 Xenopus laevis
2581 Homo sapiens
403916 Canis lupus familiaris
533428 Bos taurus
14420 Mus musculus
314360 Rattus norvegicus
693322 Macaca mulatta
423394 Gallus gallus
100156917 Sus scrofa
Selected quality suppliers for Galactosylceramidase Proteins (GALC)
Did you look for something else?